CCA
CPRX

Column Capital Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Column Capital Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$3.51K Hold
300
– – ﹤0.01% 623
2023
Q2 		$4.03K Hold
300
– – ﹤0.01% 630
2023
Q1 		$4.97K Hold
300
– – ﹤0.01% 641
2022
Q4 		$5.58K Buy
+300
New +$4.62K ﹤0.01% 601

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Column Capital Advisors's CPRX Position: Q3 2023 in Review

Column Capital Advisors held its Catalyst Pharmaceutical (CPRX) position steady in Q3 2023 at 300 shares worth $3.51K. The position accounts for ﹤0.01% of the portfolio, ranked #623.

Column Capital Advisors first reported a position in CPRX in Q4 2022 and has held it in 4 quarters since. The position peaked at $5.58K in Q4 2022. 255 funds tracked by Wall St. Rank hold CPRX as of Q3 2023.

  • Column Capital Advisors held 300 shares of Catalyst Pharmaceutical worth $3.51K as of Q3 2023.
  • Column Capital Advisors left its Catalyst Pharmaceutical share count unchanged in Q3 2023.
  • Catalyst Pharmaceutical made up ﹤0.01% of Column Capital Advisors's portfolio in Q3 2023, its #623 holding.
  • Column Capital Advisors first reported a position in Catalyst Pharmaceutical in Q4 2022 and has held it in 4 quarters since.
  • Column Capital Advisors's Catalyst Pharmaceutical position peaked at $5.58K in Q4 2022.
  • 255 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.